Lunai Bioworks (LNAI) Cash & Equivalents (2011 - 2026)

Lunai Bioworks' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 241.85% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 241.85% YoY), while the FY2025 annual figure was $92700.0, down 57.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $3.2 million, up from $491645.0 in the prior quarter.
• The five-year high for Cash & Equivalents was $11.2 million in Q1 2022, with the low at $92700.0 in Q2 2025.
• The 5-year median for Cash & Equivalents is $624808.0 (2025), against an average of $2.6 million.
• The sharpest annual moves came in 2023 and 2026: Cash & Equivalents plunged 94.08% in 2023, then soared 241.85% in 2026.
• Lunai Bioworks' Cash & Equivalents stood at $4.1 million in 2022, then slumped by 94.08% to $243980.0 in 2023, then advanced by 27.78% to $311764.0 in 2024, then soared by 57.7% to $491645.0 in 2025, then soared by 541.78% to $3.2 million in 2026.
• Business Quant data shows LNAI's Cash & Equivalents at $3.2 million in Q1 2026, $491645.0 in Q4 2025, and $624808.0 in Q3 2025.